Metabiomed

메타바이오메드 · 059210

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$71.3M (₩98.4B)

Overview

Metabiomed makes two core medical products: synthetic absorbable sutures, surgical threads that dissolve harmlessly inside the body after healing, and dental materials used to treat and restore teeth while preserving the natural tooth.

Hospitals, surgical teams, and dental clinics worldwide use its products. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company earns roughly half its revenue from dental materials and instruments and most of the remainder from its suture business.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$74.6M

▲ +9.5% YoY

Operating profit · FY2025

US$15.5M

▲ +24.4% YoY

Net income · FY2025

US$7.8M

▼ −51.8% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$60.2M(₩83.1B)	US$68.1M(₩94B)	US$74.6M(₩103B)
Operating profit	US$7.8M(₩10.7B)	US$12.5M(₩17.2B)	US$15.5M(₩21.4B)
Net income	US$7.1M(₩9.8B)	US$16.2M(₩22.3B)	US$7.8M(₩10.8B)

Revenue

FY2023US$60.2M
FY2024US$68.1M
FY2025US$74.6M

Operating profit

FY2023US$7.8M
FY2024US$12.5M
FY2025US$15.5M

Net income

FY2023US$7.1M
FY2024US$16.2M
FY2025US$7.8M

Key ratios (FY2025)

ROE

8.6%

Debt/Eq

49.4%

Op. margin

20.8%

Net margin

10.5%

Rev. YoY

▲ +9.5%

Why it matters

Metabiomed operates through several overseas subsidiaries, including units in China, Vietnam, Germany, and Japan, giving it a direct international distribution footprint rather than relying solely on third-party distributors.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?